TrialUnited European gastroenterology journal2026

Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.

Jean-Frédéric Colombel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.